Core Viewpoint - The completion of subject enrollment in the Phase IIa study for ASC30, a novel GLP-1 receptor agonist for obesity treatment, marks a significant milestone in the development of this innovative therapy [1] Company Summary - Songlei Pharmaceutical-B (01672.HK) has announced the completion of subject enrollment for its monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30 in the United States [1] - The study involved 65 participants, all of whom are either obese or overweight individuals with at least one weight-related comorbidity [1] - The CEO of Songlei, Dr. Wu Jinzi, highlighted the importance of this milestone, indicating substantial progress in the development of ASC30 [1] Product Summary - ASC30 is the first and only small molecule GLP-1 receptor agonist that can be administered either orally once daily or via subcutaneous injection once a month to once a quarter [1] - The product is designed for both weight loss treatment and weight maintenance therapy, aimed at long-term weight management [1] - ASC30 features a prolonged apparent half-life of 46 days and a superior peak-to-trough ratio of approximately 1.5, positioning it as a promising monthly treatment option for obesity [1] - Topline data from the Phase IIa study is expected to be available in the first quarter of 2026 [1]
歌礼制药-B(01672.HK)完成小分子GLP-1R激动剂ASC30治疗肥胖症的每月一次皮下储库型治疗制剂的美国IIa期研究受试者入组